

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Please cancel claims 1 to 61

62. (New) A method for the treatment of a disease or disorder of the mucosa, the method comprising administering to a subject in need of such treatment a medicament comprising negatively charged lipid assemblies loaded with an active ingredient.

63. (New) A method according to Claim 62, wherein the mucosa is the mucosa of the gastrointestinal tract (GI).

64. (New) A method according to Claim 62, wherein the lipid assemblies are liposomes.

65. (New) The method of Claim 63, wherein said GI mucosa is selected from intestinal mucosa, small bowel mucosa, large bowel mucosa or the mucosa in the rectum.

66. (New) The method of Claim 65, wherein said mucosa is the intestinal mucosa.

67. (New) The method of Claim 62, wherein said lipid assemblies comprise one or more anionic lipids selected from 1,2-distearoyl-*sn*-glycero-3-[phospho-*rac*-(1-glycerol)] (DSPG), hydrogenated soy phosphoglycerol.

68. (New) The method of Claim 62, wherein said disease or disorder is associated with a condition selected from inflammation and long term oxidative stress short term oxidative stress

69. (New) A method according to Claim 68, wherein the disease or disorder is selected from ulcerative colitis, Crohn's disease, gastric ulceration, duodenal ulceration, ileitis, colitis, ileocolitis, ulcerative proctitis, gastroenteritis, diverticulitis, diverticulosis, reflux, ulcer, gastritis, dyspepsia, nausea, abrasion to gastrointestinal tract.

70. (New) The method of Claim 68, wherein said disease or disorder is associated with inflammation, and said medicament comprises an active ingredient is an agent effective in inhibiting inflammatory responses.

71. (New) A method according to Claim 70, wherein the active agent is selected from: steroids, salicylates, COX-

In re of: BARENHOLZ17

2 inhibitors, anti-TNF α drugs, antibiotics, immunosuppressors, immunomodulators and antioxidants.

72. (New) A method according to Claim 71, wherein the active agent is selected from Prednisone, Prednisolone, methylprednisolone, methylprednisolone succinate, Budesonide, derivatives of 5-aminosalicylic acid, Sulfasalazine. Mesalamine (5ASA), Olsalazine Balsalazide, Metronidazole Ciprofloxacin, Probiotics g. Cyclosporin A, Azathioprine, Methotrexate and 6-Mercaptopurine

73. (New) The method of Claim 68, wherein said disease or disorder is associated with oxidative stress, and said medicament comprises as an active ingredient one or more anti-oxidants.

74. (New) The method of claim 73 wherein the active agent is selected from tocopherol, free radicals scavengers, SOD and SOD mimics, catalase or therapeutic reducing agents

75. (New) The method of Claim 68, wherein said disease or disorder is selected from ulcerative colitis, Crohn's disease, irritable bowel syndrome, colon carcinoma and familial adenomatous polyposis.

76. (New) A method for the prevention of a disease or disorder of the mucosa, the method comprising administering

In re of: BARENHOLZ17

to a subject in need of such treatment a medicament comprising positively charged lipid assemblies loaded with an active ingredient.

77. (New) A method according to Claim 76, wherein the mucosa is the mucosa of the gastrointestinal tract (GI).

78. (New) A method according to Claim 77, wherein the lipid assemblies are liposomes.

79. (New) A method according to Claim 77, wherein said lipid assemblies comprise one or more cationic lipids selected from 1,2-dioleyloxy-3-(trimethylamino) propane (DOTAP); cholesterol, dioctadecylmethylammonium bromide (DODAB), N-[1-(2,3,-ditetradecyloxy)propyl]-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE); N-[1-(2,3,-dioleyloxy)propyl]-N,N-dimethyl-N-hydroxy ethylammonium bromide (DORIE); N-[1-(2,3-dioleyloxy) propyl]-N,N,N-trimethylammonium chloride (DOTMA); 3β [N-(N',N'-dimethylaminoethane) carbamoyl] cholesterol (DC-Chol); and dimethyldioctadecylammonium (DDAB), N,N-dimethyl- 2,3-bis[(1-oxo-9-octadecenyl)oxy]-1-propanaminium, (DOSPA), N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium), and N-palmitoyl D-erythro sphingosyl-1-carbamoyl spermine (CCS).